Egalet Corp. (EGLT) Sees Unusually-High Trading Volume
Egalet Corp. (NASDAQ:EGLT) shares saw unusually-strong trading volume on Tuesday . Approximately 339,316 shares changed hands during mid-day trading, an increase of 40% from the previous session’s volume of 241,798 shares.The stock last traded at $9.06 and had previously closed at $8.34.
A number of analysts have recently weighed in on EGLT shares. Zacks Investment Research lowered shares of Egalet Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Cantor Fitzgerald reiterated a “buy” rating on shares of Egalet Corp. in a research note on Tuesday, June 28th.
The stock’s market cap is $203.58 million. The company’s 50 day moving average is $7.16 and its 200-day moving average is $6.56.
Egalet Corp. (NASDAQ:EGLT) last announced its quarterly earnings data on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.15. The company earned $3.45 million during the quarter, compared to analysts’ expectations of $3.83 million. During the same quarter in the previous year, the business earned ($1.03) EPS. Egalet Corp.’s revenue was up 259.4% compared to the same quarter last year. Equities research analysts expect that Egalet Corp. will post ($3.47) EPS for the current year.
In related news, CEO Robert S. Radie sold 15,000 shares of the firm’s stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $5.01, for a total transaction of $75,150.00. Following the transaction, the chief executive officer now directly owns 259,900 shares in the company, valued at $1,302,099. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert S. Radie sold 5,000 shares of the firm’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $5.07, for a total value of $25,350.00. Following the transaction, the chief executive officer now owns 259,900 shares in the company, valued at $1,317,693. The disclosure for this sale can be found here.
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.